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Use of Animal Models Has Not Contributed to Development
of Acute Stroke Therapies
Pro
Markku Kaste, MD, PhD, FAHA
In the beautiful archipelago of Stockholm, there was a satellitesymposium in connection with the World Congress of Med-
icine in 1980. The role of calcium was then a hot topic in the
cerebral ischemic cascade.1 A paper presented at the symposium
demonstrated that a calcium blocker was able to decrease the
size of brain infarction in rats. Already then I had a few
reservations about such experimental models. In a laboratory, an
investigator can modify all known confounding factors and the
time from onset of ischemia to the administration of an experi-
mental drug. The body temperature, blood pressure, blood
glucose, and acid-base balance of animals can be kept constant
and within normal physiological ranges. In a busy emergency
room, where an elderly stroke patient is admitted with many
severe concomitant diseases, ie, fragile diabetes, untreated hy-
pertension, recent myocardial infarction, and imminent heart
failure, the treating physician has major problems in balancing
them while the time from onset of symptoms is, at best, an
educational guess. I pointed out my doubts and asked whether
the treatment would have an equal efficacy in humans as it had
in rats. There was no good answer. Twenty-four years later and
having been a principal investigator and a steering committee
member in many acute stroke trials, I still have my doubts.
Since the early days of neuroprotecting agents in treatment
of acute stroke, more than 700 drugs have been studied and
more than 4000 papers describing their neuroprotective effi-
cacy have been published,2 and yet none of those drugs has
been accepted by regulatory authorities to be used for
treatment of patients with acute stroke in the United States or
the European Union. There are many reasons for the failures3
and we are still on the learning curve, but is this endless
optimism of the Village Idiot4 fruitful? The evidence from
position emission tomography studies has revealed that with-
out early reperfusion, either spontaneously or induced by
thrombolysis, the size of the final brain infarction can only
marginally be reduced with neuroprotecting agents because
the critically hypoperfused area accounts for the largest
proportion (mean 70%) of the final infarct volume.5 Accord-
ingly, even if neuroprotectants could prevent the maturation
of the ischemic penumbra to an infarct by half, like they do in
animal models, it would only reduce the size of the final
infarction by 15%. It would ask for a trial with tens of
thousands of stroke patients to prove such a hypothesis. My
estimation is based on the assumption that thrombolysis is
superior to neuroprotectant therapy and the fact that
thrombolytic trials with a longer than 3-hour time window
have all failed. To be positive, thrombolytic trials in which IV
rtPA was initiated within a 4.5- to 6-hour time window should
have enrolled 4500 patients.6
Have I learned anything else from taking part in clinical acute
stroke trials based on drugs that have been found to be effective
in animal models but to perceive many reasons for the failure of
those trials? There is no doubt that I have gained lots of
experience, which has improved the daily stroke patient care at
our department. Without our participation in many neuropro-
tectant and thrombolytic trials, our stroke triage developed as
part of these trials would certainly be less well organized. With
lots of training, our present record of the door-to-needle time for
rtPA is 12 minutes, which includes clinical examination, labo-
ratory tests, computed tomography, and informed consent. Fur-
thermore, we have enrolled more patients with stroke in the
official register for rtPA-treated stroke patients, the SITS-
MOST, than any other center in Europe.7
Animal models have helped us better understand the
pathophysiology of ischemic brain damage, but have they
otherwise contributed much to clinical practice so far? I
cannot say that they have, whereas randomized, clinical trials
(RCTs) have had a major impact. The need of discipline, an
essential part of any RCT, has influenced ordinary patient
care in many positive ways. I do not expect either that more
developed animal models could contribute to emergency
stroke care so that a neuroprotective agent would be able to
reduce the volume of an infarct in patients with stroke by 50%
as they do in rats, at least if the therapy is not combined with
thrombolysis or other neuroprotective therapies.8 If, however,
one means by the use of animal models studies aimed at
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enhancing neuronal regeneration after acute stroke, the land-
scape changes to a truly bright one. Here the Holy Grail of
clinical stroke therapies waits for those who are worthy.9 In
an innovative animal model, Lee and colleagues presented
strong data for cAMP response element-binding protein
(CREB) family transcription factors in recovery from exper-
imental hypoxic ischemic brain damage and that drugs can be
used to enhance neuronal recovery.10 Their observations may
open a highway not only for neuronal recovery and reorga-
nization after stroke, but also in Alzheimer disease, spinal
cord injuries, and in many other neurologic diseases, which
now so desperately wait for breakthroughs.9,10
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Use of Animal Models Has Not Contributed to Development
of Acute Stroke Therapies
Con
Marc Fisher, MD; Turgut Tatlisumak, MD, PhD
The development of therapies for acute ischemic stroke(AIS) has proven to be a difficult and challenging
endeavor, reflecting the complexity of the pathophysiology
and clinical aspects of this heterogeneous disorder. With only
one currently approved therapy for AIS, tPA initiated within
3 hours of stroke onset, there is only a limited track record to
assess the use of animal models in the development of AIS
therapies. A negative perspective can be taken that a large
number of interventions demonstrated efficacy in animal
models of AIS and these interventions, primarily neuropro-
tective agents, have not been shown to improve AIS outcome
in patients.1 This pessimism about the value of animal models
for providing help in the development of AIS therapies must
be viewed cautiously because there are many reasonable
explanations for the lack of translation of therapeutic benefit
in animal stroke models into successful clinical trials. The
potential reasons for lack of translational success were
previously well summarized and reflect problems both in how
animal modeling was conducted to assess therapies and also
how clinical trials were performed.2,3 The Table provides an
overview of these contentious issues.
The potential use of animal models for helping to develop
AIS therapies should be viewed from several perspectives. It
is now widely appreciated that the pathophysiology of tissue
injury in AIS is at once both simple and complex.4 Simple in
that the intraluminal blood flow compromise induced by a
thrombus or embolus initiates an increasingly complex array
of potential contributory mechanisms of cellular and subcel-
lular injury that vary depending on the level of blood flow
compromise, the metabolic milieu, genetic environment, and
other confounders. Animal modeling has certainly contrib-
uted to our understanding of these mechanisms of ischemic
injury and helped to identify potential therapeutic targets for
new interventions currently being tested in clinical trials.5
Additionally, animal models provide a mechanism to evaluate
the temporal and spatial evolution of ischemic brain injury
using advanced imaging techniques such as diffusion/perfu-
sion magnetic resonance imaging (MRI), and these tech-
niques can then be adapted to patients with AIS to evaluate
these same characteristics.6 The idea of the ischemic penum-
bra, initially suggested by animal studies, is central to the
therapeutic time window concept that is being exploited to
develop AIS therapies that potentially can be effective at later
time points, as exemplified by the Desmoteplase MRI-based
preliminary trial.7,8 It is only with the availability of increas-
ing knowledge about AIS pathophysiology and temporal
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evolution provided by animal models that novel therapies at
increasingly delayed time points can be developed.
Using animal stroke models for the development of AIS
therapies in the future should be approached carefully and
rigorously. It must be recognized that no animal stroke model
will precisely mimic human AIS, a condition that is quite
heterogeneous. Recognizing the inherent limitations of ani-
mal stroke modeling should provide important lessons for
both basic and clinical stroke researchers. Animal modeling-
based treatment experiments must be performed to answer
specific, goal-oriented questions. Choosing the most appro-
priate experimental conditions to address questions about a
drug’s therapeutic time window, dose–response relationship,
and side effect profile should provide valuable information to
help in the design of subsequent clinical trials. If a drug has
a short time window in a model with a well-characterized
time period of penumbral survival and a narrow therapeutic
index of efficacy to safety, then it is unlikely that the agent
represents a good candidate for clinical development. Animal
studies should be used to predict likely futility to eliminate
drugs not likely to succeed in clinical trials, as well as to
identify favorable drugs that should proceed to clinical
development. Initial suggestions that are now widely used by
the pharmaceutical industry for a preclinical assessment
paradigm for novel AIS therapies were made by the STAIR
group in 1999 and recently expanded on.5,9 Conversely, a
favorable therapeutic profile in stroke models does not
guarantee success in clinical development, especially if the
clinical trial program repeats the flawed approaches used to
assess many drugs in the past. As AIS therapy development
evolves toward combination approaches, the performance of
good preclinical studies will assume increasing importance to
help determine optimal dosing regimens for maximal efficacy
and to evaluate the potential for interactions among the drug
combinations. These issues will be critical for helping to
determine how to best initiate clinical trials.
The field of AIS therapeutics has been littered with many
failures and only rare successes. To blame animal stroke
modeling as a primary culprit for these failures may be
convenient but not accurate. In fact, the narrow therapeutic
time window observed with most neuroprotective drugs may
actually have predicted the lack of efficacy observed with
these agents in clinical trials in which most patients were
treated 5 to 6 hours or longer after stroke onset.10 Going
forward, information from animal modeling should be heeded
and the lessons learned incorporated into clinical trial design.
It is entirely likely that the combination of improved preclin-
ical assessment and clinical trial design/implementation will
conjointly expedite the development of novel AIS therapies.
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Potential Problems With Prior Animal and Clinical Studies for
Acute Stroke Therapies
Animal Studies
1. Studies used healthy, young animals without comorbid conditions
2. Animal experiments were performed under anesthesia and involved a
surgical procedure to induce arterial occlusion
3. The occlusion did not involve a clot
4. Physiological parameters were not well-controlled
5. Studies were not done in a strictly randomized, double-blind fashion
6. Prolonged survival studies were not performed to document a
persistent treatment effect
7. Histology was the primary outcome and treatment effects on
sophisticated functional outcome measures were not performed
8. Drug treatment was started before induction of ischemia or very early
after that at a time point not relevant to the clinical condition
9. Adverse effects of novel neuroprotective agents may have been
overlooked
Clinical Studies
1. An appropriate time window was not used based on preclinical data
2. Adequate drug levels were not achieved because of toxicity
3. The mechanism of drug action was not considered in the trial design,
ie, drugs with no effect on white matter injury included patients with
lacunar stroke
4. Outcome assessment of a therapeutic response was not adjusted for
baseline severity
5. The outcome assessment was not adapted to the mechanism of drug
action
6. The trial included too many mild or severe patients
7. Many clinical trials were initiated on the basis of insufficient preclinical
data
8. Insufficient statistical power
9. Protocol violations
2325
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Stroke Drug Development
Usually, But Not Always, Animal Models
Geoffrey A. Donnan, MD, FRACP; Stephen M. Davis, MD, FRACP
In 2005, the standard mode of drug development is todetermine its biologic mechanism, efficacy, dosage, and
time window in preclinical animal models. The only licensed
acute pharmacologic intervention for stroke is tPA, which
traveled this conventional route before proof of its efficacy in
pivotal clinical trials.1 Many stroke clinicians have been
perplexed by the failure of other compounds trialed over the
past 2 decades, despite strong evidence for efficacy in animal
models. Indeed, the specter of investigator fatigue is raised in
the face of continued negative results, chiefly from trials of
neuroprotectants.
Fisher nicely argues that there are many reasons why
translation of neuroprotectants from animal models to clinical
practice has not occurred and, indeed, this has been the theme
of a series of STAIR recommendations. Our personal bias is
that a large number of neuroprotectants have had inadequate
preclinical testing in differing models, species, and appropri-
ate time windows. For example, there is little justification for
human studies of an agent that reduces infarct volumes in a
single rat model by 30% with inappropriately short time
windows.
As argued by Fisher, there is also often a poor understand-
ing of the model itself; knowledge of the presence and
duration of the ischemic penumbra is critical. Trial method-
ology has now become much more sophisticated, and nega-
tive results are more like to be the result of biologically weak
compounds.2 In addition, treatment effect sizes are likely to
have been overestimated, and we would not expect an
absolute risk reduction of more than approximately 3% to 5%
for neuroprotectants, substantially lower than for
thrombolytic therapy. We are firmly of the view that larger
sample sizes are required for these trials than are currently
used.
One inescapable fact highlighted by Kaste is that the rigor
of case selection and patient management in clinical trials has
driven the standards of acute stroke care. This may be a factor
in the lower-than-expected mortality rates in many trials.
Also, such efficiencies may explain the impressive record
door-to-needle time of 12 minutes from the center of our
protagonist from Finland!
One striking exception to the conventional pathway of drug
development has been the positive results using recombinant
factor VIIa to attenuate hematoma growth in patients with
primary intracerebral hemorrhage.3 The biologic plausibility
of this approach was based on clinical studies of the dynamics
of hematoma growth documented by repeated computed
tomography scans rather than animal models. The compound
was already in clinical use as a hemostatic agent for another
indication. This illustrates our view that although the majority
of candidate stroke compounds need to be evaluated in
preclinical animal models, there is always a place for astute
clinicians to recognize the potential of compounds already in
use for another clinical indication.
Despite the recent history of failure of translation of
neuroprotectants into clinical practice, promising trial results
have been recently released for a free radical trapping agent.
The development of this compound was based on a rigorous
preclinical program, including multiple animal models and
careful adherence to the STAIR criteria.4 This message
should not be lost on investigators hoping for success in the
tough world of translational stroke research.
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